These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37839939)

  • 21. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.
    Gangat N; McCullough K; Al-Kali A; Begna KH; Patnaik MM; Litzow MR; Hogan W; Shah M; Alkhateeb H; Mangaonkar A; Foran JM; Palmer JM; Pardanani A; Tefferi A
    Br J Haematol; 2022 Aug; 198(4):e54-e58. PubMed ID: 35614565
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
    Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How I manage anemia related to myelofibrosis and its treatment regimens.
    Verstovsek S
    Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
    Harrison CN; Talpaz M; Mead AJ
    Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
    Pardanani A; Tefferi A; Jamieson C; Gabrail NY; Lebedinsky C; Gao G; Liu F; Xu C; Cao H; Talpaz M
    Blood Cancer J; 2015 Aug; 5(8):e335. PubMed ID: 26252788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
    Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
    Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fedratinib in myelofibrosis.
    Mullally A; Hood J; Harrison C; Mesa R
    Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.
    Passamonti F; Heidel FH; Parikh RC; Ajmera M; Tang D; Nadal JA; Davis KL; Abraham P
    Future Oncol; 2022 Jun; 18(18):2217-2231. PubMed ID: 35388710
    [No Abstract]   [Full Text] [Related]  

  • 36. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
    Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
    Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
    Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
    Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
    Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.